| Indicators | Browse All

Palvella Therapeutics, Inc. (PVLA)

Healthcare | Biotechnology | Wayne, United States | NasdaqGM
149.97 USD -0.36 (-0.239%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 149.97

Short-term:★★★⯪☆Long-term:★★★☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 3:42 a.m. EDT

The most compelling signal here is the stark contrast between the company's deteriorating historical price performance and its robust current balance sheet. While the nine-year cumulative return sits at a painful minus sixty percent, the latest annual year-over-year change reversed sharply to plus one hundred ninety percent, signaling a market pivot toward the pipeline's potential. Fundamentally, the business is burning cash with negative free flow, yet it holds a fortress-like liquidity position with two hundred fifty million dollars in cash against minimal debt. This safety net allows management to pursue aggressive growth without immediate dilution pressure, which aligns with the strong buy consensus and the nearly ninety percent upside to the mean analyst target. However, investors must recognize this is a speculative bet on clinical success rather than a cash cow; the high risk rating and lack of profitability mean the long-term trajectory remains volatile despite the recent recovery.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.054845
AutoARIMA0.055432
AutoTheta0.067511
AutoETS0.132443

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 35%
H-stat 1.17
Ljung-Box p 0.164
Jarque-Bera p 0.000
Excess Kurtosis 2.50
Attribute Value
Sector Healthcare
Debt to Equity Ratio 10.441
Market Cap 2,160,828,928
Forward P/E -20.00
Website https://palvellatx.com

As of Aug. 22, 2026, 3:42 a.m. EDT: Speculators are positioning for upside with heavy call open interest in November and February expirations, particularly at the $150 strike. Put activity is concentrated in September with more in-the-money protection, suggesting a hedge against near-term volatility. Implied volatility remains elevated across the board, reflecting uncertainty around the drug development timeline.


Info Dump

Attribute Value
52 Week Change 1.8520205
Address1 353 W. Lancaster Avenue
Address2 Suite 200
All Time High 780.0
All Time Low 6.2
Ask 195.41
Ask Size 2
Audit Risk 7
Average Analyst Rating 1.0 - Strong Buy
Average Daily Volume10 Day 196,760
Average Daily Volume3 Month 257,456
Average Volume 257,456
Average Volume10Days 196,760
Bid 111.17
Bid Size 2
Board Risk 7
Book Value 15.065
City Wayne
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 9
Country United States
Crypto Tradeable 0
Currency USD
Current Price 149.97
Current Ratio 21.179
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 152.94
Day Low 148.565
Debt To Equity 10.441
Display Name Palvella Therapeutics
Earnings Call Timestamp End 1,785,846,600
Earnings Call Timestamp Start 1,785,846,600
Earnings Timestamp 1,785,846,600
Earnings Timestamp End 1,794,400,200
Earnings Timestamp Start 1,794,400,200
Ebitda Margins 0.0
Enterprise Value 1,932,886,784
Eps Current Year -6.37077
Eps Forward -7.498
Eps Trailing Twelve Months -4.85
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 144.5923
Fifty Day Average Change 5.377701
Fifty Day Average Change Percent 0.037192166
Fifty Two Week Change Percent 185.20206
Fifty Two Week High 161.38
Fifty Two Week High Change -11.410004
Fifty Two Week High Change Percent -0.07070271
Fifty Two Week Low 50.82
Fifty Two Week Low Change 99.15
Fifty Two Week Low Change Percent 1.9510036
Fifty Two Week Range 50.82 - 161.38
Financial Currency USD
First Trade Date Milliseconds 1,420,209,000,000
Float Shares 10,622,166
Forward Eps -7.498
Forward P E -20.001333
Free Cashflow -25,446,624
Full Exchange Name NasdaqGM
Full Time Employees 29
Fullday Change -0.360001
Fullday Change Percent -0.239474
Fullday Price 149.97
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,785,542,400
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.11595
Held Percent Institutions 1.04108
Implied Shares Outstanding 14,408,407
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,713,830,400
Last Split Factor 1:80
Long Business Summary Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Long Name Palvella Therapeutics, Inc.
Market us_market
Market Cap 2,160,828,928
Market State CLOSED
Max Age 86,400
Message Board Id finmb_534271315
Most Recent Quarter 1,782,777,600
Net Income To Common -61,696,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 2,163,458,332
Number Of Analyst Opinions 15
Open 148.65
Operating Cashflow -36,513,000
Operating Margins 0.0
Overall Risk 8
Payout Ratio 0.0
Phone 484 253 1461
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 149.97
Post Market Time 1,787,959,804
Previous Close 150.33
Price Eps Current Year -23.540325
Price Hint 2
Price To Book 9.954863
Profit Margins 0.0
Quick Ratio 21.008
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.0
Region US
Regular Market Change -0.360001
Regular Market Change Percent -0.239474
Regular Market Day High 152.94
Regular Market Day Low 148.565
Regular Market Day Range 148.565 - 152.94
Regular Market Open 148.65
Regular Market Previous Close 150.33
Regular Market Price 149.97
Regular Market Time 1,787,947,200
Regular Market Volume 191,991
Return On Assets -0.22055
Return On Equity -0.46625
Sand P52 Week Change 0.20504117
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 8
Shares Outstanding 14,408,407
Shares Percent Shares Out 0.1492
Shares Short 2,149,544
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 2,177,331
Short Name Palvella Therapeutics, Inc.
Short Percent Of Float 0.1688
Short Ratio 10.65
Source Interval 15
State PA
Symbol PVLA
Target High Price 270.0
Target Low Price 205.0
Target Mean Price 230.53333
Target Median Price 232.0
Total Cash 250,584,000
Total Cash Per Share 17.392
Total Debt 22,642,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -4.85
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 116.71248
Two Hundred Day Average Change 33.257523
Two Hundred Day Average Change Percent 0.28495258
Type Disp Equity
Volume 191,991
Website https://palvellatx.com
Zip 19,087